Litigation Details for Bristol-Myers Squibb Company v. Apotex Inc. (D. Del. 2017)

Bristol-Myers Squibb Company v. Apotex Inc. (D. Del. 2017)

Docket		Date Filed	2017-10-24
Court	District Court, D. Delaware	Date Terminated	2018-02-14
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	6,087,383
Link to Docket	External link to docket

Details for Bristol-Myers Squibb Company v. Apotex Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-10-24				External link to document
2017-10-24	1		”), prior to expiration of U.S. Patent No. 6,087,383 (“the ’383 patent”). …. This is an action for patent infringement arising under the patent laws of the United States, … PATENT-IN-SUIT 10. On July 11, 2000, the U.S. Patent and Trademark Office…copy of the ’383 patent is attached hereto as Exhibit A. The claims of the ’383 patent are valid and enforceable…of the ’383 patent and has the right to enforce it. The expiration date of the ’383 patent is December	External link to document
2017-10-24	11	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number US 6,087,383. (etg) (Entered: 07… 14 February 2018 1:17-cv-01493 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2017-10-24	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,087,383. (lmm) (Entered: … 14 February 2018 1:17-cv-01493 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Bristol-Myers Squibb v. Apotex, 1:17-cv-01493: Eliquis Patent Litigation Summary

Last updated: August 3, 2026

Bristol-Myers Squibb Company and related entities sued Apotex Inc. in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act over Apotex’s abbreviated new drug application for generic Eliquis, the apixaban anticoagulant. The dispute concerned patents covering apixaban and Eliquis formulations. The case was resolved through the broader Eliquis generic litigation settlement program and did not produce a final trial judgment on patent validity or infringement.

The litigation protected BMS and Pfizer’s U.S. Eliquis franchise from immediate generic entry. Publicly reported settlement terms for the Eliquis generic defendants generally authorized U.S. entry in 2028, subject to the terms of individual agreements and earlier-entry contingencies.[1]

What was Bristol-Myers Squibb v. Apotex about?

The case was a patent-infringement action triggered by Apotex’s filing of an ANDA seeking FDA approval to market generic apixaban tablets.

Item	Case detail
Case	Bristol-Myers Squibb Company v. Apotex Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-01493
Judge	Richard G. Andrews
Legal pathway	Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)
Reference product	Eliquis tablets
Active ingredient	Apixaban
Brand companies	Bristol-Myers Squibb and Pfizer
Generic applicant	Apotex Inc.
Primary commercial issue	Timing of generic apixaban entry
Resolution	Settlement and dismissal, without a public merits judgment

BMS alleged that Apotex’s ANDA submission constituted an artificial act of infringement because the proposed generic product would infringe listed Eliquis patents if commercially marketed in the United States. The case was part of a wider group of patent suits against generic manufacturers that filed Paragraph IV certifications challenging Eliquis patent protection.

Which patents did BMS assert against Apotex?

The principal Eliquis patent at issue in the litigation was U.S. Patent No. 6,967,208, commonly referred to as the ’208 patent. The patent covers apixaban, including the compound used as the active pharmaceutical ingredient in Eliquis.

Public Eliquis litigation records also identify later-issued formulation and treatment patents, including U.S. Patent Nos. 9,326,945 and 9,326,946, as part of the broader patent estate. The exact patent claims and counts asserted against each ANDA filer depended on the defendant’s proposed product, ANDA certifications and the timing of the complaint.

Patent	General subject matter	Commercial relevance
U.S. Patent No. 6,967,208	Apixaban compound and related pharmaceutical claims	Core active-ingredient protection
U.S. Patent No. 9,326,945	Apixaban pharmaceutical formulation claims	Potential barrier to generic tablet formulation
U.S. Patent No. 9,326,946	Apixaban treatment-related claims	Method-of-use protection, depending on listed indication and carve-out

The ’208 patent was the central composition patent. Formulation and method-of-use patents could extend practical protection after the principal compound patent, although their value depends on claim scope, Orange Book listing status, claim construction and whether a generic applicant can lawfully omit the protected indication or formulation feature.

When did the Eliquis patents expire?

The core Eliquis patent estate had staggered expiration dates. The ’208 patent was listed with an expiration date in December 2026, subject to applicable patent-term adjustments and pediatric exclusivity. The later formulation patent protection extended into 2028.

Protection	Approximate U.S. end date	Effect
’208 compound patent	December 2026	Primary active-ingredient barrier
Pediatric exclusivity associated with Eliquis	2027, if applicable to the relevant protection	Six-month regulatory extension
’945 formulation patent	February 2028	Potential formulation barrier
Broader settlement-based entry date	Generally 2028	Contractual generic-entry restriction

FDA Orange Book records should control for the current listed patent status and expiration dates. Patent-term adjustments, pediatric exclusivity and later Orange Book changes can affect the effective regulatory date.[2]

The practical commercial date was more important than the earliest nominal patent expiration. A generic company could potentially challenge the ’208 patent and seek approval after that patent expired, but a separate formulation patent could delay commercial launch if it remained valid, enforceable and applicable to the proposed product.

Did Apotex file a Paragraph IV challenge?

Yes. The litigation arose from Apotex’s ANDA filing and Paragraph IV certification process.

A Paragraph IV certification states that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product. Under 21 U.S.C. § 355(j)(5)(B)(iii), the certification gives the brand company a basis to sue for infringement before FDA approval. A timely patent suit generally creates a 30-month stay of final approval, subject to statutory exceptions and court action.

The important distinction is that the Paragraph IV filing did not establish that the patents were invalid. It created the procedural mechanism for the dispute. Because the Apotex case settled, the court did not issue a public final decision determining whether Apotex’s proposed product infringed or whether the asserted patents were valid.

What was the litigation timeline?

Date	Event
2017	BMS filed the Delaware patent action against Apotex after the ANDA and Paragraph IV process
2017-2021	The parties litigated claim construction, infringement, validity and regulatory stay issues within the Hatch-Waxman framework
2022	BMS reached settlements with Apotex and other Eliquis generic defendants
2022-2023	The Apotex action was resolved through dismissal proceedings reflected in the public docket
2026-2028	Relevant patent and settlement dates become commercially significant for generic launch planning

The case should not be treated as a reported invalidity or noninfringement victory for Apotex. Nor should it be treated as a final infringement victory for BMS. The commercial result came from settlement rather than an adjudicated merits outcome.

What was the settlement impact on generic Eliquis entry?

The Eliquis settlement program preserved a substantial period of branded exclusivity after the ’208 patent’s nominal expiration.

Public reporting stated that BMS and Pfizer reached agreements with multiple generic companies allowing U.S. generic apixaban entry in 2028. The commonly reported date was April 1, 2028, although individual agreements could contain different provisions, earlier-entry rights or acceleration mechanisms.[1]

The settlement therefore had three effects:

1. It removed the immediate risk of an adverse Paragraph IV judgment.
2. It converted uncertain litigation exposure into a defined future entry framework.
3. It preserved branded Eliquis sales beyond the expiration of the core compound patent.

The settlement terms were not publicly disclosed in full. The public docket does not provide a complete economic analysis of any consideration paid, launch license structure, supply terms, authorized-generic provisions or acceleration rights.

What is the Orange Book status of Eliquis?

Eliquis is an FDA-approved small-molecule drug, not a biologic. Biosimilar rules do not apply. Generic applicants must use the ANDA pathway and address the listed patents through Paragraph I, II, III or IV certifications, or through a section viii statement for a method-of-use patent.

The Orange Book is central to the case because it identifies the patents that BMS and Pfizer listed for Eliquis and provides the regulatory framework for patent certification and approval timing.[2]

Relevant regulatory issues include:

• Whether a patent was listed for the specific Eliquis strength and dosage form.
• Whether the ANDA applicant submitted a Paragraph IV certification.
• Whether the patent claims covered the proposed generic product.
• Whether the generic applicant could omit a patented indication through a section viii statement.
• Whether the 30-month stay had expired or had been terminated.
• Whether FDA approval could proceed after patent expiration or settlement-authorized entry.

Because Eliquis is a small molecule, the primary competitive threat is generic substitution rather than biosimilar competition.

How strong was the BMS Eliquis patent estate?

The estate was commercially strong but legally mixed in structure.

Core compound protection

The ’208 patent provided the strongest type of protection because it covered the active ingredient itself. A successful challenge to the compound patent could have opened the market to products using apixaban, subject to remaining formulation, method-of-use and regulatory barriers.

Formulation protection

Formulation patents can be narrower than compound patents. Their strength depends on whether the generic product necessarily practices each claimed feature, such as excipient composition, concentration, dosage-form characteristics or manufacturing parameters.

A generic company may avoid infringement by using a noninfringing formulation. That possibility makes formulation patents less predictable as a complete market barrier, although they can still delay entry or increase launch risk.

Method-of-use protection

Method-of-use claims may be vulnerable to a section viii carve-out if the generic applicant omits the patented indication from its labeling. Their practical strength depends on label language, prescribing behavior, induced-infringement evidence and the scope of the FDA-approved indications.

Manufacturing and process barriers

Process patents can increase manufacturing risk but usually do not provide the same market-wide barrier as a valid compound patent. A generic manufacturer may redesign its process, use a different supplier or produce the active ingredient through an alternative route.

Overall, BMS had a layered estate. The compound patent created the principal barrier, while formulation and use patents increased litigation leverage and complicated generic launch planning.

What generic launch risks existed for Apotex?

Apotex faced four principal risks.

Approval delay

The Paragraph IV litigation could delay final FDA approval through the statutory 30-month stay. The stay’s effect depended on the timing of the suit, the applicable patent listings and later court or FDA actions.

Infringement liability

If BMS prevailed, Apotex could have faced an injunction or an order preventing commercial launch until patent expiration. A court could also impose damages for conduct occurring after approval if the product were marketed in violation of the judgment.

Formulation redesign

Even if Apotex defeated the compound patent, it might have needed to modify its formulation or labeling to avoid later-listed patents.

Settlement restrictions

The settlement likely reduced litigation uncertainty but postponed commercial entry. For Apotex, that tradeoff exchanged the possibility of an earlier launch for a defined 2028 entry framework.

What litigation status affects Bristol-Myers Squibb v. Apotex today?

The case is no longer an active merits dispute. The public record reflects settlement-related resolution and dismissal rather than a final trial decision. No public judgment in the case establishes that the asserted Eliquis patents were invalid, unenforceable or not infringed.

The principal continuing legal significance is therefore indirect:

• The case formed part of the Eliquis Paragraph IV litigation network.
• The settlement reduced near-term generic-entry uncertainty.
• The patent estate remains relevant to the timing of generic apixaban approval and launch.
• Future disputes may concern settlement interpretation, launch rights, patent listing changes or later patents rather than the original merits claims.

How does Apotex compare with other Eliquis generic defendants?

Apotex was one of multiple ANDA filers challenging Eliquis protection. The competitive landscape was not limited to one generic manufacturer. Other companies pursued their own Paragraph IV strategies, and BMS negotiated a broader set of settlements.

Factor	Apotex litigation	Other Eliquis generic cases
Product	Generic apixaban tablets	Generic apixaban tablets
Regulatory pathway	ANDA	ANDA
Patent mechanism	Paragraph IV challenge	Paragraph IV challenges
Main risk	Compound and formulation patent enforcement	Same, depending on asserted patents
Resolution pattern	Settlement and dismissal	Mixed litigation and settlement outcomes
Commercial timing	Generally tied to broader 2028 framework	Agreement-specific

The competitive risk after entry will depend on how many manufacturers receive approval at the same time. Multiple launches can produce rapid price erosion, while a limited first-wave launch can preserve higher generic margins for the initial entrants.

What revenue exposure did the settlement protect?

Eliquis is one of the largest products in the BMS and Pfizer portfolios. Early generic entry would have affected:

• U.S. Eliquis net sales.
• Gross-to-net pricing.
• Contracting leverage with pharmacy benefit managers.
• Hospital and health-system purchasing.
• International reference pricing.
• Portfolio valuation and forecasts.

The settlement did not eliminate eventual generic erosion. It shifted the expected U.S. erosion date into 2028 and reduced the probability of a substantially earlier launch following a successful Paragraph IV challenge.

The financial value of the settlement depended on U.S. Eliquis sales at the time of entry, the number of simultaneous generic launches, authorized-generic strategy, payer substitution and the extent of any pediatric or formulation-based exclusivity.

Key Takeaways

• Bristol-Myers Squibb sued Apotex in Delaware over an ANDA for generic Eliquis, or apixaban.
• The case was a Hatch-Waxman Paragraph IV dispute.
• U.S. Patent No. 6,967,208 was the principal compound patent in the Eliquis estate.
• Later formulation and method-of-use patents extended the potential patent barrier into 2028.
• The Apotex case ended through settlement and dismissal, not a public merits judgment.
• The settlement formed part of a broader Eliquis generic-resolution program.
• Public reporting generally placed authorized U.S. generic entry in 2028, commonly April 1, 2028.
• Biosimilar risk is irrelevant because Eliquis is a small-molecule drug subject to ANDA competition.
• The key commercial risk is coordinated or near-simultaneous generic entry after the settlement period.

FAQs About the Apotex Eliquis Patent Case

Did Apotex win the Eliquis patent case?

No public record establishes an Apotex victory on patent invalidity, unenforceability or noninfringement. The case was resolved by settlement and dismissal.

Can Apotex launch generic Eliquis before 2028?

The publicly reported settlement framework generally points to 2028 entry. Earlier launch would depend on confidential agreement terms, patent events, regulatory developments or settlement-specific acceleration provisions.

Is apixaban protected by a composition patent?

Yes. U.S. Patent No. 6,967,208 is the principal Eliquis compound patent and covers apixaban-related composition claims.

Does Eliquis have formulation patent protection?

Yes. The Eliquis estate includes later formulation-related patents, including U.S. Patent No. 9,326,945. Their practical effect depends on claim scope, validity, enforceability and the formulation used by a generic applicant.

Will Eliquis face biosimilar competition?

No. Eliquis is a chemically synthesized small-molecule drug. Its expected post-exclusivity competition is from ANDA-approved generic apixaban products, not biosimilars.

References

1. Bristol Myers Squibb. (2022). Bristol Myers Squibb and Pfizer reach settlements with generic manufacturers regarding Eliquis. Corporate press materials.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. District Court for the District of Delaware. (2017-2023). Bristol-Myers Squibb Company v. Apotex Inc., No. 1:17-cv-01493-RGA. Public docket.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center: U.S. Patent Nos. 6,967,208, 9,326,945 and 9,326,946. https://patentcenter.uspto.gov

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

6. Hatch-Waxman Act, 35 U.S.C. § 271(e)(2).